These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1287881

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 6. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y, Yajima K, Yahara H, Maruyama H, Matsumoto K, Okada K, Ueshima S, Matsuo O.
    Blood Coagul Fibrinolysis; 1992 Aug 02; 3(4):381-7. PubMed ID: 1330023
    [Abstract] [Full Text] [Related]

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 02; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D.
    Thromb Haemost; 1991 Dec 02; 66(6):684-93. PubMed ID: 1796414
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
    Rydzewski A, Castellino FJ.
    Arch Biochem Biophys; 1993 Jan 02; 300(1):472-82. PubMed ID: 8424682
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L, Lijnen HR, Van Nuffelen A, Demarsin E, Collen D.
    Thromb Haemost; 1990 Aug 13; 64(1):53-60. PubMed ID: 2148847
    [Abstract] [Full Text] [Related]

  • 14. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 13; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
    de Vries C, Veerman H, Nesheim ME, Pannekoek H.
    Thromb Haemost; 1991 Mar 04; 65(3):280-5. PubMed ID: 1904654
    [Abstract] [Full Text] [Related]

  • 18. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ, Verheijen JH.
    Arzneimittelforschung; 1992 Mar 04; 42(3):358-62. PubMed ID: 1497699
    [Abstract] [Full Text] [Related]

  • 19. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D, Lijnen HR, Bulens F, Vandamme AM, Tulinsky A, Nelles L.
    J Biol Chem; 1990 Jul 25; 265(21):12184-91. PubMed ID: 2115513
    [Abstract] [Full Text] [Related]

  • 20. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM.
    Thromb Haemost; 1991 Feb 12; 65(2):174-80. PubMed ID: 1905070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.